Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Says Global Drug Safety On Importers’ Shoulders

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA is grappling with the challenges of import safety as the number of foreign-sourced drugs entering the country exceeds FDA's inspection capabilities, and the agency hopes two risk-based draft guidances will increase industry accountability and free up resources for high-risk inspections

You may also be interested in...



FDA May Require Drug Importers To Verify Product Quality

Public meeting will solicit stakeholder comments on how FDASIA-mandated import regulations should be implemented as the expedited entry program reemerges.

FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget

The $3.2 billion U.S. FDA budget proposed May 7 by the Obama administration includes a number of proposals aimed at ensuring global drug safety, including a $166 million initiative for improving supply chain safety for medical products

FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget

The $3.2 billion U.S. FDA budget proposed May 7 by the Obama administration includes a number of proposals aimed at ensuring global drug safety, including a $166 million initiative for improving supply chain safety for medical products

Related Content

UsernamePublicRestriction

Register

SC071022

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel